Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483.

PMID:
29330218
2.

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation.

Chang C, Yang X, Fahmi OA, Riccardi KA, Di L, Obach RS.

Xenobiotica. 2017 Aug;47(8):673-681. doi: 10.1080/00498254.2016.1222640. Epub 2016 Sep 5.

PMID:
27595796
3.

A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.

Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, Maurer TS.

J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):197-209. doi: 10.1007/s10928-014-9357-1. Epub 2014 Apr 10.

PMID:
24718648
4.

Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.

Wang T, Yang Z, Zhang Z, Gong YF, Riccardi KA, Lin PF, Parker DD, Rahematpura S, Mathew M, Zheng M, Meanwell NA, Kadow JF, Bender JA.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):213-7. doi: 10.1016/j.bmcl.2012.10.120. Epub 2012 Nov 7.

PMID:
23200254
5.

Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

Southers JA, Bauman JN, Price DA, Humphries PS, Balan G, Sagal JF, Maurer TS, Zhang Y, Oliver R, Herr M, Healy DR, Li M, Kapinos B, Fate GD, Riccardi KA, Paralkar VM, Brown TA, Kalgutkar AS.

ACS Med Chem Lett. 2010 May 13;1(5):219-23. doi: 10.1021/ml100058w. eCollection 2010 Aug 12.

6.

Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists.

Didiuk MT, Griffith DA, Benbow JW, Liu KK, Walker DP, Bi FC, Morris J, Guzman-Perez A, Gao H, Bechle BM, Kelley RM, Yang X, Dirico K, Ahmed S, Hungerford W, DiBrinno J, Zawistoski MP, Bagley SW, Li J, Zeng Y, Santucci S, Oliver R, Corbett M, Olson T, Chen C, Li M, Paralkar VM, Riccardi KA, Healy DR, Kalgutkar AS, Maurer TS, Nguyen HT, Frederick KS.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4555-9. doi: 10.1016/j.bmcl.2009.07.004. Epub 2009 Jul 8.

PMID:
19625189
7.

Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus.

Terry KK, Lebel WS, Riccardi KA, Grasser WA, Thompson DD, Paralkar VM.

Prostaglandins Leukot Essent Fatty Acids. 2008 Jan;78(1):3-10. Epub 2007 Nov 26.

PMID:
18036799
8.

BMP-6 exerts its osteoinductive effect through activation of IGF-I and EGF pathways.

Grasser WA, Orlic I, Borovecki F, Riccardi KA, Simic P, Vukicevic S, Paralkar VM.

Int Orthop. 2007 Dec;31(6):759-65. Epub 2007 Jul 19.

9.

Macular pigment optical density in a midwestern sample.

Ciulla TA, Curran-Celantano J, Cooper DA, Hammond BR Jr, Danis RP, Pratt LM, Riccardi KA, Filloon TG.

Ophthalmology. 2001 Apr;108(4):730-7.

PMID:
11297490
10.

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF.

Antimicrob Agents Chemother. 2000 Aug;44(8):2093-9.

11.

Olestra consumption is not associated with macular pigment optical density in a cross-sectional volunteer sample in Indianapolis.

Cooper DA, Curran-Celentano J, Ciulla TA, Hammond BR Jr, Danis RB, Pratt LM, Riccardi KA, Filloon TG.

J Nutr. 2000 Mar;130(3):642-7.

PMID:
10702598
12.

Follow-up to the study: A randomized, double-blind, placebo-controlled consumer rechallenge test of Olean salted snacks.

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 1):2. No abstract available.

PMID:
9629591
13.

Follow-Up to the study: A randomized, double-blind, placebo-controlled consumer rechallenge test of olean salted snacks

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1998 Feb;27(1 Pt 2):2.

PMID:
9618318
14.

Randomized, double-blind, placebo-controlled, consumer rechallenge test of Olean salted snacks.

Zorich NL, Biedermann D, Riccardi KA, Bishop LJ, Filloon TG.

Regul Toxicol Pharmacol. 1997 Oct;26(2):200-9.

PMID:
9356283
15.

Olestra ingestion and dietary fat absorption in humans.

Daher GC, Cooper DA, Zorich NL, King D, Riccardi KA, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1694S-1698S. doi: 10.1093/jn/127.8.1694S.

PMID:
9237964
16.

Olestra ingestion and retinyl palmitate absorption in humans.

Daher GC, Cooper DA, Zorich NL, King D, Riccardi KA, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1686S-1693S. doi: 10.1093/jn/127.8.1686S.

PMID:
9237963
17.

Olestra dose response on fat-soluble and water-soluble nutrients in humans.

Schlagheck TG, Riccardi KA, Zorich NL, Torri SA, Dugan LD, Peters JC.

J Nutr. 1997 Aug;127(8 Suppl):1646S-1665S. doi: 10.1093/jn/127.8.1646S.

PMID:
9237961

Supplemental Content

Loading ...
Support Center